skip navigation nih record
Vol. LVIII, No. 23
November 17, 2006
cover

previous story

next story



New NCAB Members, Chair Named

  NCI director Dr. John Niederhuber (r) welcomes new NCAB members. They are (front row, from l) Dr. Karen Dow Meneses, Robert A. Ingram, Dr. Carolyn D. Runowicz. In the second row are (from l) Dr. Lloyd K. Everson, Dr. Bruce A. Chabner and Dr. Donald S. Coffey.  
  NCI director Dr. John Niederhuber (r) welcomes new NCAB members. They are (front row, from l) Dr. Karen Dow Meneses, Robert A. Ingram, Dr. Carolyn D. Runowicz. In the second row are (from l) Dr. Lloyd K. Everson, Dr. Bruce A. Chabner and Dr. Donald S. Coffey.  

The White House recently announced the appointment of seven new members to the National Cancer Advisory Board and the designation of a new NCAB chairperson. They are:

Chairperson Dr. Carolyn D. Runowicz is director, Carole and Ray Neag Comprehensive Cancer Center, Northeast Utilities chair in experimental oncology and professor of obstetrics and gynecology, division of gynecologic oncology, University of Connecticut Health Center. She is a nationally prominent expert in gynecologic cancers and women’s health and is involved in many national health organizations and professional societies.
Below are Dr. Anthony Atala (top) and Dr. Judah Folkman.
Dr. Anthony Atala
Dr. Judah Folkman

Dr. Anthony Atala is W.H. Boyce professor and director of the Wake Forest Institute for Regenerative Medicine and chair of the department of urology, Wake Forest University School of Medicine. His research in regenerative medicine and tissue engineering focuses on growing numerous new human tissues and organs to repair or replace those damaged by age, cancer, trauma or abnormal development.

Dr. Bruce A. Chabner is chief, hematology/oncology, clinical director, Massachusetts General Hospital Cancer Center, professor of medicine at Harvard Medical School and previous director of NCI’s former Division of Cancer Treatment from 1982-1995. He has a special interest in the treatment of lymphoma, with a focus on experimental new drugs, particularly natural products and signal-transduction inhibitors.

Dr. Donald S. Coffey is Catherine Iola and J. Smith Michael distinguished professor of urology, Johns Hopkins University School of Medicine. His research includes the role of the nuclear matrix in oncogenesis and the mechanism of action of androgens in inducing prostate growth and gene function during duplication of DNA and the development of cancer.

Dr. Lloyd K. Everson is vice chairman and member of the board of directors, US Oncology Inc. He works with oncologists across the country to advance the quality of care available to cancer patients.

Dr. Judah Folkman is Julia Dyckman Andrus professor of pediatric surgery at Harvard Medical School and director, Vascular Biology Program, Boston Children’s Hospital. His research has been instrumental in the discovery that tumor growth is dependent on angiogenesis, which has led to the treatment of invasive, malignant cancers and has resulted in numerous clinical trials with treatments also applied to benign diseases such as psoriasis and macular degeneration.

Robert A. Ingram is vice chairman of pharmaceuticals, GlaxoSmithKline and former chairman and chief executive officer of Glaxo Wellcome. He has served on the boards of numerous community and civic organizations such as the board of advisors for the Forum for Corporate Conscience, which advocates socially, economically and environmentally responsible, values-based business leadership.

Dr. Karen Dow Meneses is professor, Beat M. & Jill L. Kahli endowed chair in oncology nursing, University of Central Florida. Her main research interests are in breast cancer, quality of life and cancer survivorship, screening and early detection of cancer and in skin cancer prevention for adolescents for which she has received numerous honors. NIH Record Icon

back to top of page